Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary for 3.4.19.12 extracted from

  • Sivakumar, D.; Stein, M.
    Binding of SARS-CoV covalent non-covalent inhibitors to the SARS-CoV-2 papain-like protease and ovarian tumor domain deubiquitinases (2021), Biomolecules, 11, 802 .
    View publication on PubMedView publication on EuropePMC
Search for more literature for 3.4.19.12

Application

Application Comment Organism
pharmacology covalent docking plus MD refinement of a representative set of known SARS-CoV inhibitors into OTUB2, OTUB1, and the PLpro from SARS-CoV-2 to probe their inhibitor binding and rationalize a deubiquitinase selectivity. It is pointed out that the structural differences in cellular deubiquitinases suggest that these enzymes may be different enough to be selectively targeted Homo sapiens

Inhibitors

Inhibitors Comment Organism Structure
additional information the binding of SARS-CoV covalent and non-covalent inhibitors to the SARS-CoV-2 papain-like protease and ovarian tumor domain deubiquitinases (OTUB1 and OTUB2) is studied; the binding of SARS-CoV covalent and non-covalent inhibitors to the SARS-CoV-2 papain-like protease and ovarian tumor domain deubiquitinases (OTUB1 and OTUB2) is studied Homo sapiens

Organism

Organism UniProt Comment Textmining
Homo sapiens Q96DC9
-
-
Homo sapiens Q96FW1
-
-

Synonyms

Synonyms Comment Organism
OTUB1
-
 Homo sapiens
OTUB2
-
 Homo sapiens
Otubain-1
-
 Homo sapiens
Otubain-2
-
 Homo sapiens

General Information

General Information Comment Organism
physiological function the enzyme is essential for viral replication Homo sapiens